

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Brii Biosciences Limited

腾盛博药生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2137)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE

This announcement is made by the board of directors (“**Board**”) of Brii Biosciences Limited (the “**Company**”) on a voluntary basis.

The Board is pleased to announce that TSB Therapeutics (Beijing) Co., Ltd. (“**TSB Therapeutics**”), a joint venture majority-owned by the Company, has initiated a Phase 2 clinical trial in China for its severe acute respiratory syndrome coronavirus 2 (“**SARS-CoV-2**”) neutralizing antibodies, BRII-196 and BRII-198. This study will be led by Dr. Nanshan Zhong, the Academician of the Chinese Academy of Engineering and Director of the National Clinical Medical Research Center for Respiratory Diseases at the First Affiliated Hospital of Guangzhou Medical University, and conducted at clinical centers in Beijing Ditan Hospital, Guangzhou Eighth People’s Hospital, and Shenzhen Third People’s Hospital.

In early 2020, the Company partnered with Tsinghua University and Shenzhen Third People’s Hospital to establish TSB Therapeutics for the development of BRII-196 and BRII-198, non-competing SARS-CoV-2 neutralizing antibodies derived from recovering coronavirus disease 2019 (“**COVID-19**”) patients. The two antibodies, BRII-196 and BRII-198, target distinct epitope regions in the receptor binding domain in coronavirus spike glycoproteins non-competitively, and are being developed as a “cocktail”, or combination therapy, with a goal of retaining efficacy against current and future variants and preventing the generation and selection of resistant viruses.

BRII-196 and BRII-198 have completed Phase 1 clinical trials as individual monotherapies in China. The results showed that both BRII-196 and BRII-198 were safe and well-tolerated in healthy Chinese participants with predicted pharmacokinetic profiles. The BRII-196 and BRII-198 antibody “cocktail” is currently being evaluated in a Phase 1 combination study in healthy subjects in China and in Phase 3 of the master trial protocols developed by the National Institutes of Health of United States of America as part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines program being conducted by the United States National Institute of Allergy and Infectious Diseases globally among ambulatory COVID-19 patients who are at high risk for disease progression. Recent preclinical studies have also shown that this cocktail combination therapy may maintain neutralizing activity against the SARS-CoV-2 variants, which continue to be of global concern, including Alpha (α), Beta (β) and Gamma (γ) variants. Evaluation of emerging variants is underway.

Cautionary Statement: There is no assurance that BRII-196 and BRII-198 will ultimately be successfully developed or marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, July 20, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Zhi Hong and Mr. Yongqing Luo as executive directors; Mr. Robert Taylor Nelsen and Dr. Axel Bouchon, as non-executive directors; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui and Mr. Gregg Huber Alton as independent non-executive directors.